





# DP18-1815 | 2018 – 2021 Performance Measures Snapshot

## Improving the Health of Americans Through Prevention and Management of Diabetes and Heart Disease and Stroke

### Strengthen team-based care and community-clinical linkages

DP18-1815 recipients are **working with health care systems and community organizations** to strengthen policies and processes to **increase engagement of non-physicians** (including community health workers, and pharmacists) in caring for patients with high blood pressure (HBP) and high blood cholesterol (HBC).



### Percentage of patients within health care systems...



Implementing new or enhanced team-based care approaches or policies to address: **Blood Pressure Control** and **Cholesterol Management**



That have policies or systems to encourage self-measured blood pressure monitoring with clinical support for patients with hypertension



Who have **HBP** that are referred to an evidence-based lifestyle program

Who have **HBC** that are referred to an evidence-based lifestyle program

2018 value    Increase from 2018    2023 Target



**10,796 Community Health Workers (CHWs)** are covered under state efforts to expand CHW curricula and training delivery vehicles, CHW certification systems, and/or CHW payment mechanisms, an increase of 5,405 (100%) from 2018



**1,782 pharmacists** provide MTM for patients with HBP to promote medication self-management and lifestyle modification, an increase of 29 pharmacists (1.6%) from 2018

**1,695 pharmacists** provide MTM for patients with HBC to promote medication self-management and lifestyle modification, an increase of 3 pharmacists (.2%) from 2018

### These efforts have ultimately reduced cardiovascular disease risks among adults with known high blood pressure and high blood cholesterol.



of adults with known high blood pressure have **achieved blood pressure control** (7% improvement from 2018)



of patients considered at high-risk of cardiovascular events have their **cholesterol managed** with statin therapy (22% improvement from 2018)



of patients with a diagnosis of hyperlipidemia who have been **prescribed a lipid lowering therapy** (29% improvement from 2018)

Note: Based on recipient reported data from July 1, 2020 to June 30, 2021; the number of recipients reporting differs for each measure. Data represents proportional progress achieved to date with respect to total population each recipient aims to engage by target year 2023

For more information please contact [DHDSPEvaluation@cdc.gov](mailto:DHDSPEvaluation@cdc.gov). DRAFT: 03/31/2022

